首页 > 文献资料
-
西地那非联合多沙唑嗪缓释剂治疗勃起功能障碍合并良性前列腺增生相关下尿路症状患者疗效的开放对照多中心临床评估
-
年龄、人体测量学和代谢综合征危险因素是否与勃起功能障碍病人的下尿路症状相关?一项前瞻性研究
Aim: To evaluate the effects of metabolic profiles on lower urinary tract symptoms (LUTS) in men with erectile dysfunction (ED). Methods: A total of 75 impotent men aged 25-75 years old (mean 58.1 years) were included in the study on a prospective basis. Patients were evaluated with a complete history, physical examination, anthropometry and metabolic profiles. LUTS were assessed using the International Prostate Symptom Score (IPSS). Results:Overall, there was no correlation between the IPSS and continuous parameters. However, when continuous variables were categorized, some parameters were significantly associated with LUTS. Patients with triglyceride level of 150 mg/Dl or higher had more severe symptoms than those with tiglyceride levels less than 150 mg/Dl (19.4 ± 2.4vs. 14.3 ± 1.1, P = 0.033). When 40 mg/Dl was chosen as the high-density lipoprotein (HDL)-cholesterol cut-off level, the IPSS was significantly different between the two groups divided by 40 mg/Dl (19.4 ± 2.6 for HDL-cholesterol < 40 mg/Dl vs. 14.4 ± 1.0 for HDL-cholesterol ≥ 40 mg/Dl, P = 0.042). The area under the receiver operating characteristic curve (AUROCC) of triglyceride was 65.7% (95% confidence interval [CI], 52.6%-82.3%; P = 0.034)for severe LUTS. However, the AUROCC for 'HDL-cholesterol' was not significant (area, 65.4%; 95% CI, 48.2%-82.7%;P = 0.062). No other factors were determined to be significant in this regard. Conclusion: The results of the present study indicate that some metabolic profiles might influence LUTS in men with ED.
-
用α-阻断剂疗法治疗由前列腺增生引起下尿路症状病人的勃起功能障碍